Business Context and Reporting Period
Company: vTv Therapeutics Inc. (VTVT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: vTv is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for diabetes and chronic diseases. Its lead candidate, cadisegliatin, is a liver-selective glucokinase activator currently in a Phase 3 trial (CATT1) for Type 1 diabetes. The company operates as a holding company with its principal operating subsidiary, vTv Therapeutics LLC.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2025 |
Six Months Ended June 30, 2025 |
Six Months Ended June 30, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $1,000 |
| Net Loss (Attributable to vTv) | $(6,046) | $(11,138) | $(10,045) |
| Net Loss Per Share (Basic & Diluted) | $(0.92) | $(1.69) | $(1.97) |
| Operating Expenses | $7,721 | $14,224 | $13,782 |
| Research & Development | $4,103 | $6,933 | $6,088 |
| General & Administrative | $3,618 | $7,291 | $7,694 |
| Cash and Cash Equivalents (End of Period) | $25,922 | $25,922 | $45,526 |
| Net Cash Used in Operating Activities | N/A | $(10,782) | $(14,064) |
| Accumulated Deficit | $(310,856) | $(310,856) | $(291,301) |
Material Changes vs. Prior Period
- Revenue: The company reported $0 revenue for the six months ended June 30, 2025, compared to $1.0 million in the same period in 2024. The prior year revenue was driven by a development milestone satisfaction under the Newsoara License Agreement.
- Operating Expenses: Total operating expenses increased by $442,000 (3.2%) year-over-year for the six-month period.
- R&D Expenses: Increased by $845,000 (13.9%) primarily due to higher indirect costs (payroll) and spending on other projects, partially offset by lower direct spending on the cadisegliatin program.
- G&A Expenses: Decreased by $403,000 (5.2%) due to reductions in legal fees, payroll, and other operating costs, partially offset by an increase in share-based compensation.
- Liquidity: Cash and cash equivalents decreased by $10.8 million during the six months ended June 30, 2025, compared to an increase of $36.1 million in the prior year period. The prior year increase was driven by a $51.0 million private placement financing.
- Net Loss: Net loss attributable to vTv Therapeutics Inc. increased by $1.1 million for the six-month period compared to the prior year.
Outlook, Risks, and Management Commentary
- Clinical Progress: The FDA removed a clinical hold on the cadisegliatin program on March 14, 2025. The company reinitiated patient screening in May 2025 and randomized the first subject in the CATT1 Phase 3 trial in August 2025. Top-line data is expected in the second half of 2026.
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $310.9 million and requires additional financing to fund operations and clinical trials.
- Financing Strategies: The company is evaluating direct equity investments and potential licensing/monetization of other programs. It maintains an At-The-Market (ATM) offering agreement with TD Cowen for up to $50.0 million; $47.5 million remains available as of June 30, 2025.
- Collaboration Update: A Second Amendment to the Newsoara License Agreement, which required a $20.0 million upfront fee for global rights, became null and void as of June 26, 2025, as the fee was not paid within the one-year window.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for substantial additional capital, potential dilution from future equity offerings, and the company's history of losses.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $25.9 million cash balance against the projected burn rate for the CATT1 Phase 3 trial and other operations.
- Financing Plans: Confirm the status of any new financing discussions or the utilization of the remaining $47.5 million ATM facility.
- Clinical Trial Status: Monitor patient enrollment rates in the CATT1 trial and the timeline for top-line data (expected H2 2026).
- Noncontrolling Interest: Review the 18.1% noncontrolling interest in vTv LLC and the terms of the Exchange Agreement regarding potential cash or share exchanges.
- Intellectual Property: Note the recent allowance of claims for the crystalline salt form of cadisegliatin by the USPTO in August 2025.